DITROPAN XL Drug Patent Profile

When do Ditropan Xl patents expire, and when can generic versions of Ditropan Xl launch?

Ditropan Xl is a drug marketed by Janssen Pharms and is included in one NDA.

The generic ingredient in DITROPAN XL is oxybutynin chloride. There are sixteen drug master file entries for this compound. Thirty-nine suppliers are listed for this compound. Additional details are available on the oxybutynin chloride profile page.

DrugPatentWatch^® Litigation and Generic Entry Outlook for Ditropan Xl

A generic version of DITROPAN XL was approved as oxybutynin chloride by TEVA PHARMS USA on November 14^th, 1988.

Summary for DITROPAN XL

US Patents:	0
Applicants:	1
NDAs:	1
Raw Ingredient (Bulk) Api Vendors:	99
Clinical Trials:	23
Patent Applications:	1,885
Drug Prices:	Drug price information for DITROPAN XL
DailyMed Link:	DITROPAN XL at DailyMed

See drug prices for DITROPAN XL

Recent Clinical Trials for DITROPAN XL

Identify potential brand extensions & 505(b)(2) entrants

Sponsor	Phase
Seoul National University Hospital	Phase 2
Il-Yang Pharm. Co., Ltd.	Phase 2
Necmi Kadıoğlu Hospital	NA

See all DITROPAN XL clinical trials

US Patents and Regulatory Information for DITROPAN XL

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Janssen Pharms	DITROPAN XL	oxybutynin chloride	TABLET, EXTENDED RELEASE;ORAL	020897-001	Dec 16, 1998		DISCN	Yes	No
Janssen Pharms	DITROPAN XL	oxybutynin chloride	TABLET, EXTENDED RELEASE;ORAL	020897-002	Dec 16, 1998		DISCN	Yes	No
Janssen Pharms	DITROPAN XL	oxybutynin chloride	TABLET, EXTENDED RELEASE;ORAL	020897-003	Jun 22, 1999		DISCN	Yes	No

Expired US Patents for DITROPAN XL

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	Patent No.	Patent Expiration
Janssen Pharms	DITROPAN XL	oxybutynin chloride	TABLET, EXTENDED RELEASE;ORAL	020897-002	Dec 16, 1998	5,840,754*PED
Janssen Pharms	DITROPAN XL	oxybutynin chloride	TABLET, EXTENDED RELEASE;ORAL	020897-003	Jun 22, 1999	4,783,337*PED
Janssen Pharms	DITROPAN XL	oxybutynin chloride	TABLET, EXTENDED RELEASE;ORAL	020897-002	Dec 16, 1998	4,612,008*PED

International Patents for DITROPAN XL

See the table below for patents covering DITROPAN XL around the world.

Country	Patent Number	Title	Estimated Expiration
United Kingdom	9723081
United Kingdom	2140687	OSMOTIC DRUG DELIVERY SYSTEM
Spain	532018

Market Dynamics and Financial Trajectory for DITROPAN XL

Last updated: February 20, 2026

What is DITROPAN XL?

DITROPAN XL (oxybutynin chloride extended-release) is a prescription medication used primarily for overactive bladder (OAB) symptoms, including urinary urgency, frequency, and incontinence. It is marketed by Johnson & Johnson and introduced as an extended-release formulation to improve compliance and reduce side effects linked to immediate-release forms.

Market Overview

Size and Growth

The global overactive bladder market was valued at approximately $4.4 billion in 2022. It is projected to grow at a compound annual growth rate (CAGR) of around 6.2% through 2030, driven by aging populations, increased diagnosis rates, and expanded therapeutic indications.

Key Players

• Johnson & Johnson (producer of DITROPAN XL)
• UroGen Pharma (rival products)
• Allergan (now part of AbbVie)
• Pfizer and Others

Market Share

Johnson & Johnson holds an estimated 55% share of the branded OAB market, with DITROPAN XL contributing significantly to revenues. Competitors, including generic formulations, account for the remainder.

Regulatory and Pricing Environment

Approval Timeline

• DITROPAN XL was approved by the FDA in 2004.
• The drug received CE marking in Europe in 2005.

Pricing and Reimbursement

• Average wholesale price (AWP) in the US: approximately $325 per month.
• Reimbursement policies vary by country; insurance coverage highly influences sales volume.

Patent Status

• The original patent expired around 2013.
• Johnson & Johnson has efforts to extend exclusivity through formulation patents, but many generics entered the market post-2013.

Financial Trajectory

Revenue Trends

Between 2010 and 2022, DITROPAN XL generated:

Year	Revenue (USD million)	Notes
2010	850	Peak prior to patent expiration
2013	770	Slight decline due to generic entry
2015	600	Accelerated decline, generic penetration begins
2018	450	Continued erosion, market shift toward generics
2022	390	Stabilized but reduced revenue trend

Profitability

Gross margins for DITROPAN XL typically ranged between 65-70%, with net margins declining as generic competition increased. R&D costs for reformulations or new line extensions have remained minimal relative to sales.

Outlook

• Revenue is expected to decline further, especially as biosimilar competition could further erode market share post-2025.
• Lifecycle management strategies include reformulations, combination products, or expanding indications to offset revenue declines.

Future Market Drivers

• Aging populations in developed markets will sustain demand.
• Growing awareness leads to higher diagnosis and treatment rates.
• Potential approval of new formulations or combination therapies could mitigate revenue erosion.
• Patent challenges or patent term extensions will influence timing of generic competition.

Risks and Constraints

• Patent expirations continue to pressure pricing and profitability.
• Competitive launches of non-invasive neuromodulation devices and alternative therapies threaten market share.
• Reimbursement shifts and pricing pressures in key markets like the US and Europe can impact revenue streams.

Strategic Implications

Johnson & Johnson's focus on lifecycle extension through innovative delivery mechanisms and new indications is crucial. The shift toward personalized medicine may influence future R&D investments. Diversification into other therapeutic areas could mitigate risks associated with declining DITROPAN XL revenues.

Key Takeaways

• DITROPAN XL remains a significant product within the OAB market but faces declining revenue from generic competition.
• The global market for bladder disorder treatments will grow modestly, emphasizing aging demographics.
• Revenue declines are expected to persist unless new formulations or indications achieve approval.
• Patent expirations around 2013 catalyzed generic entry, contributing to revenue erosion.
• Strategic focus should include pipeline innovation and market diversification.

FAQs

1. What factors led to the decline of DITROPAN XL revenues?
Patent expiration around 2013 enabled generic competitors, leading to pricing pressure and market share loss.

2. How does the competition from generics impact DITROPAN XL sales?
Generics are priced approximately 50-60% lower, reducing brand revenue and encouraging substitution.

3. Are there ongoing efforts to extend DITROPAN XL’s market exclusivity?
Johnson & Johnson has filed for new formulation patents and is exploring expanded indications; however, significant patent barriers may be limited.

4. What alternative treatments are gaining traction in the OAB market?
Neuromodulation devices and novel oral agents with different mechanisms of action are emerging.

5. How will demographic changes influence the DITROPAN XL market?
Aging populations globally will sustain demand for OAB therapies, potentially stabilizing the market despite generic competition.

---

References

[1] Market Research Future. (2022). Overactive Bladder Market Forecast.
[2] Johnson & Johnson Annual Reports. (2010–2022).
[3] U.S. Food and Drug Administration. (2004). DITROPAN XL approval documentation.
[4] IMS Health. (2022). Prescription Drug Price Trends.
[5] European Medicines Agency. (2005). DITROPAN XL CE marking documentation.